DSIP

Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide consisting of nine amino acids in the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It was first isolated in 1974 by Swiss researchers who identified it in the cerebral venous blood of rabbits during slow-wave sleep induction. When infused into the mesodiencephalic ventricle of recipient animals, the peptide reliably produced spindle and delta EEG activity characteristic of deep, restorative sleep ^[1]. DSIP is found endogenously in the hypothalamus, limbic system, pituitary, and peripheral organs, suggesting broad physiological roles beyond sleep alone.

The precise mechanism by which DSIP promotes sleep remains incompletely understood. In vitro, the peptide has a very short half-life of roughly 15 minutes due to degradation by aminopeptidase-like enzymes. Proposed mechanisms include enhancement of slow-wave delta sleep, modulation of melatonin release, and dampening of corticotropin-releasing factor (CRF)-mediated stress arousal pathways. Some research also implicates DSIP in regulating circadian rhythm entrainment and reducing basal corticosterone levels.

Human clinical data on DSIP is limited and the results are mixed. A double-blind study in chronic insomnia patients found that DSIP produced statistically significant increases in total sleep time compared to placebo ^[3], though the effect size was described as weak. A separate study found some evidence of benefit on sleep architecture in the night following infusion. Researchers have also observed potential stress-buffering effects, and animal studies suggest neuroprotective and antioxidant properties.

The research base for DSIP is substantially thinner than for better-studied sleep peptides, and no well-powered phase III human trials have been completed. The peptide's instability in plasma complicates both its study and its therapeutic application. Users should understand that its clinical utility for insomnia remains unproven by rigorous standards.